Shun Lu

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 308 citations · Full text

Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth

Xiangyun Ye, Xiaomin Niu, Gu linping et al. · Oncotarget · 2016 · 163 citations · Full text

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Clinical Oncology · 2020 · 151 citations

Advanced Nsclc, Stage Iv/recurrent Nsclc, Pd-l1 Expression +11

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer, Changli Wang, Fumihiro Tanaka et al. · Journal of Clinical Oncology · 2021 · 135 citations

Surgical Oncology, Cancer Management, Surgery +19

The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer

Tingting Lü, Ziming Li, Ying Yang et al. · Cancer Letters · 2018 · 88 citations

Tumor Biology, Tissue Development, Hippo/yap1 Pathway Interacts +6